Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 27;62(8):e00224-18.
doi: 10.1128/AAC.00224-18. Print 2018 Aug.

Molecular Confirmation of the Linkage between the Rhizopus oryzae CYP51A Gene Coding Region and Its Intrinsic Voriconazole and Fluconazole Resistance

Affiliations

Molecular Confirmation of the Linkage between the Rhizopus oryzae CYP51A Gene Coding Region and Its Intrinsic Voriconazole and Fluconazole Resistance

Daiana Macedo et al. Antimicrob Agents Chemother. .

Abstract

Rhizopus oryzae is the most prevalent causative agent of mucormycosis, an increasingly reported opportunistic fungal infection. These Mucorales are intrinsically resistant to Candida- and Aspergillus-active antifungal azole drugs, such as fluconazole (FLC) and voriconazole, respectively. Despite its importance, the molecular mechanisms of its intrinsic azole resistance have not been elucidated yet. The aim of this work was to establish if the Rhizopus oryzaeCYP51 genes are uniquely responsible for intrinsic voriconazole and fluconazole resistance in these fungal pathogens. Two CYP51 genes were identified in the R. oryzae genome. We classified them as CYP51A and CYP51B based on their sequence similarity with other known fungal CYP51 genes. Later, we obtained a chimeric Aspergillus fumigatus strain harboring a functional R. oryzae CYP51A gene expressed under the regulation of the wild-type A. fumigatusCYP51A promoter and terminator. The mutant was selected after transformation by using a novel procedure taking advantage of the FLC hypersusceptibility of the A. fumigatusCYP51A deletion mutant used as the recipient strain. The azole susceptibility patterns of the A. fumigatus transformants harboring R. oryzae CYP51A mimicked exactly the azole susceptibility patterns of this mucormycete. The data presented in this work demonstrate that the R. oryzae CYP51A coding sequence is uniquely responsible for the R. oryzae azole susceptibility patterns.

Keywords: CYP51; Mucorales; Rhizopus; azole; fluconazole; intrinsic resistance; molecular mechanism; resistance; voriconazole.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Agarose gel (1.5% agarose) electrophoresis at 40 V for 3 h showing the detection of R. oryzae CYP51 transcripts using genomic DNA (lanes 1 and 3) and cDNA (lanes 2 and 4) as the templates. Lanes 1 and 2, amplification of RoCYP51A (RO3G_16595) 1,626-nt and 1,524-nt bands, respectively; lanes 3 and 4, the resolved PCR bands of RoCYP51B (RO3G_11790) at 1,755 nt and 1,533 nt, respectively.
FIG 2
FIG 2
Neighbor-joining phylogenetic tree of 55 different fungal 14-α sterol demethylases, including enzymes from 9 Ascomycetes yeast species, 20 Ascomycetes mold species, 9 Basidiomycetes species, and 7 Mucorales species. GenBank accession numbers appear after the species names. Some fungal genus names were abbreviated as follows to esthetically improve the figure: A., Aspergillus; S., Saccharomyces; C., Candida; F., Fusarium; R., Rhizopus.
FIG 3
FIG 3
(A, B) Selection plates using FLC (100 μg/ml) where LMDM-1229 (A) and LMDM-1230 (B) transformants were obtained. (C, D) Replica plates used minimal medium (C) and minimal medium with 450 μg/ml hygromycin B (D).
FIG 4
FIG 4
(A) Scheme of the LMDM-p134 vector generation process used in this work. Striped and black boxes represent the 5′ and 3′ UTRs of the AfCYP51A included and not included in the transformation vector, respectively. Light gray boxes denote the RoCYP51A (RO3G_16595) complete coding sequence obtained from cDNA. Dark gray boxes show the C- and N-terminal fractions of AfCYP51A (12, 32). Thin lines in LMDM-p125 and LMDM-p134 symbolize the pGEM-T Easy vector. Arrows represent primers, and their coloring shows where they hybridized to each of the genomic or vector DNAs. (B) Integration and homologous recombination confirmation by using PCRs. Lane M, 100-nt ladder (numbers on the left are in nucleotides); lanes 1 to 4, RoCYP51A (RO3G_16595) exon 3 amplifications using the P-RoCYP51F3 and P-RoCYP51R3 primers (1,374 nt); lanes 5 to 8, multiplex PCR with the A13, A5R and P-RoCYP51R1 primers to confirm homologous recombination (by the presence of the 1,286-nt band) or the lack of existence of RoCYP51A (RO3G_16595) in the A. fumigatus genome (by the presence of the 1,461-nt band); lane 1, LMDM-p134; lanes 2 and 5, R. oryzae ATCC 11886; lanes 3 and 6, A. fumigatus LMDM-1229; lane 7, A. fumigatus LMDM-1230; lanes 4 and 8, A. fumigatus LMDM-32.
FIG 5
FIG 5
Disk diffusion susceptibility testing using fluconazole (FLC) and voriconazole (VRC) paper disks for LMDM-31 (parental strain akuBKU80Δ) (31), LMDM-32 (recipient strain akuBKU80Δ CYP51AΔ) (12), R. oryzae ATCC 11886, and A. fumigatus chimera LMDM-1229 (akuBKU80Δ RoCYP51A).

Similar articles

Cited by

References

    1. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II. 2005. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191:1350–1360. doi:10.1086/428780. - DOI - PubMed
    1. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50:1091–1100. doi:10.1086/651263. - DOI - PubMed
    1. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. 2012. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 54(Suppl 1):S23–S34. doi:10.1093/cid/cir866. - DOI - PubMed
    1. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41: 634–653. doi:10.1086/432579. - DOI - PubMed
    1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, B DePauw, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group . 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415. doi:10.1056/NEJMoa020191. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources